Co-administration of fluoxetine with clopidogrel reduced the area under the curve and maximum plasma concentrations of clopidogrel active metabolite by 20.6% and 25.3%, respectively.
Drug-drug interactions may contribute to the variability of the response of clopidogrel. Several hypotheses have been proposed concerning the potential modification of clopidogrel pharmacokinetics and pharmacodynamics by fluoxetine. This open-label crossover study assessed the effect of fluoxetine on the pharmacological activity of clopidogrel in healthy volunteers. Eight healthy male volunteers received a single 600-mg loading dose of clopidogrel followed by 20 mg of fluoxetine on 4 days and then 20 mg of fluoxetine plus 600 mg of clopidogrel on the fifth day. Eleven blood samples were withdrawn after clopidogrel administration to determine plasma concentrations of clopidogrel active metabolite (CAM) and platelet function. Platelet aggregation was measured by light transmittance aggregometry (LTA) and platelet reactivity index by flow cytometric vasodilator-stimulated phosphoprotein (VASP) analysis. The areas under the curve and maximum plasma concentrations of CAM were, respectively, 20.6 and 25.3% lower after co-administration of fluoxetine compared with administration of clopidogrel alone. The percentage maximum platelet aggregation values in the presence of 5 μM and 10 μM adenosine diphosphate, measured by LTA, were, respectively, 13.9 and 22.4% lower after fluoxetine co-administration. The platelet reactivity index measured by the flow cytometric VASP method was 36.8% lower when clopidogrel was administered in conjunction with fluoxetine.
Delavenne et al. (Sun,) conducted a other in Healthy volunteers (n=8). Fluoxetine and clopidogrel co-administration vs. Clopidogrel alone was evaluated on Pharmacological activity of clopidogrel (plasma concentrations of clopidogrel active metabolite and platelet function). Co-administration of fluoxetine with clopidogrel reduced the area under the curve and maximum plasma concentrations of clopidogrel active metabolite by 20.6% and 25.3%, respectively.